PDS Biotechnology Corporation announced promising clinical trial results for a triple combination therapy targeting HPV-associated cancers, published in JAMA...

Pyxis Oncology’s PYX-201, an antibody-drug conjugate targeting Extradomain-B Fibronectin (EDB+FN), received Fast Track Designation from the FDA for treating...

Quantum BioPharma Ltd. announced the successful completion of a Phase 1 clinical trial for Lucid-MS, a novel neuroprotective compound...

Plus Therapeutics completed its Phase 1 single-dose escalation trial of Rhenium (¹⁸⁶Re) Obisbemeda, administered intrathecally, for patients with leptomeningeal...

Regeneron Pharmaceuticals announced that the FDA accepted its resubmitted Biologics License Application (BLA) for odronextamab. The drug is intended...

In this interview, we sit down with Catherine (Cat) Hall, Head of GXP Quality at Egnyte, to discuss how...

Emalex Biosciences’ Phase 3 trial of ecopipam, a dopamine-1 receptor antagonist, demonstrated statistically significant improvement in Tourette syndrome symptoms...

Coya Therapeutics is advancing COYA 303, a combination therapy of low-dose interleukin-2 (COYA 301) and a GLP-1 receptor agonist,...

Ligand Pharmaceuticals has invested $50 million and led a syndicate of co-investors, including Paragon Biosciences, Valor Equity Partners, and...